AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Clinical Pearls
- The study showed that about 39% (12 of 31) of patients in the enzalutamide arm had AR-V7 detected in their circulating tumor cells.
- Every patient taking enzalutamide that had AR-V7 did not obtain a PSA response to enzalutamide.
- In the abiraterone arm, 19% (6 of 31) were found to have AR-V7.
- Similarly, all of these patients demonstrated resistance to abiraterone. ​
<<<
Recent Videos
Related Content
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025Article
The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
